<- Go Home
Aerovate Therapeutics, Inc.
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Market Cap
$70.7M
Volume
396.4K
Cash and Equivalents
$31.1M
EBITDA
-$90.0M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$32.41
52 Week Low
$1.25
Dividend
N/A
Price / Book Value
0.88
Price / Earnings
-0.82
Price / Tangible Book Value
0.88
Enterprise Value
-$17.4M
Enterprise Value / EBITDA
0.20
Operating Income
-$90.3M
Return on Equity
82.06%
Return on Assets
-48.67
Cash and Short Term Investments
$88.7M
Debt
$540.0K
Equity
$80.5M
Revenue
N/A
Unlevered FCF
-$46.7M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium